BioLineRx Ltd. (BLRX)
Nasdaq · Healthcare · Biotechnology
$2.32−0.85%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $11.6M
- 52-week range
- $2.15 – $4.56
- 52-week change
- −43.84%
- EPS (trailing)
- $0.00
- Next earnings
- Nov 23, 2026
About BioLineRx Ltd.
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Headquarters: Hevel Modi'in, Israel · 20 employees · biolinerx.com